196 related articles for article (PubMed ID: 11410238)
1. Amelioration of insulin resistance in diabetic ob/ob mice by a new type of orally active insulin-mimetic vanadyl complex: bis(1-oxy-2-pyridinethiolato)oxovanadium(IV) with VO(S(2)O(2)) coordination mode.
Takeshita S; Kawamura I; Yasuno T; Kimura C; Yamamoto T; Seki J; Tamura A; Sakurai H; Goto T
J Inorg Biochem; 2001 Jun; 85(2-3):179-86. PubMed ID: 11410238
[TBL] [Abstract][Full Text] [Related]
2. An orally active antidiabetic vanadyl complex, bis(1-oxy-2-pyridinethiolato)oxovanadium(IV), with VO(S2O2) coordination mode; in vitro and in vivo evaluations in rats.
Sakurai H; Sano H; Takino T; Yasui H
J Inorg Biochem; 2000 May; 80(1-2):99-105. PubMed ID: 10885469
[TBL] [Abstract][Full Text] [Related]
3. The vanadyl (VO2+) chelate bis(acetylacetonato)oxovanadium(IV) potentiates tyrosine phosphorylation of the insulin receptor.
Ou H; Yan L; Mustafi D; Makinen MW; Brady MJ
J Biol Inorg Chem; 2005 Dec; 10(8):874-86. PubMed ID: 16235045
[TBL] [Abstract][Full Text] [Related]
4. A new halogenated antidiabetic vanadyl complex, bis(5-iodopicolinato)oxovanadium(IV): in vitro and in vivo insulinomimetic evaluations and metallokinetic analysis.
Takino T; Yasui H; Yoshitake A; Hamajima Y; Matsushita R; Takada J; Sakurai H
J Biol Inorg Chem; 2001 Feb; 6(2):133-42. PubMed ID: 11293406
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction.
Stephens JM; Lee J; Pilch PF
J Biol Chem; 1997 Jan; 272(2):971-6. PubMed ID: 8995390
[TBL] [Abstract][Full Text] [Related]
6. Cytoprotective effect of bis(1-oxy-2-pyridinethiolato)oxovanadiun(IV) on myocardial ischemia/reperfusion injury elicits inhibition of Fas ligand and Bim expression and elevation of FLIP expression.
Bhuiyan MS; Shibuya M; Shioda N; Moriguchi S; Kasahara J; Iwabuchi Y; Fukunaga K
Eur J Pharmacol; 2007 Oct; 571(2-3):180-8. PubMed ID: 17658509
[TBL] [Abstract][Full Text] [Related]
7. Orally active and long-term acting insulin-mimetic vanadyl complex:bis(picolinato)oxovanadium (IV).
Sakurai H; Fujii K; Watanabe H; Tamura H
Biochem Biophys Res Commun; 1995 Sep; 214(3):1095-101. PubMed ID: 7575515
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of insulin signaling pathway in adipocytes by oxovanadium(IV) complexes.
Basuki W; Hiromura M; Adachi Y; Tayama K; Hattori M; Sakurai H
Biochem Biophys Res Commun; 2006 Oct; 349(3):1163-70. PubMed ID: 16970914
[TBL] [Abstract][Full Text] [Related]
9. Action mechanism of bis(allixinato)oxovanadium(IV) as a novel potent insulin-mimetic complex: regulation of GLUT4 translocation and FoxO1 transcription factor.
Hiromura M; Nakayama A; Adachi Y; Doi M; Sakurai H
J Biol Inorg Chem; 2007 Nov; 12(8):1275-87. PubMed ID: 17805585
[TBL] [Abstract][Full Text] [Related]
10. Morphological analysis of the pancreas and liver in diabetic KK-A(y) mice treated with zinc and oxovanadium complexes.
Moroki T; Yoshikawa Y; Yoshizawa K; Tsubura A; Yasui H
Metallomics; 2014 Sep; 6(9):1632-8. PubMed ID: 24905743
[TBL] [Abstract][Full Text] [Related]
11. Improvement of diabetes, obesity and hypertension in type 2 diabetic KKAy mice by bis(allixinato)oxovanadium(IV) complex.
Adachi Y; Yoshikawa Y; Yoshida J; Kodera Y; Katoh A; Takada J; Sakurai H
Biochem Biophys Res Commun; 2006 Jul; 345(3):945-50. PubMed ID: 16707105
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic properties of VO(dmpp)2 as assessed by in vitro and in vivo studies in type 2 diabetic GK rats.
Domingues N; Pelletier J; Ostenson CG; Castro MM
J Inorg Biochem; 2014 Feb; 131():115-22. PubMed ID: 24333827
[TBL] [Abstract][Full Text] [Related]
13. Activation of phosphatidylinositol 3-kinase/protein kinase B pathway by a vanadyl compound mediates its neuroprotective effect in mouse brain ischemia.
Shioda N; Ishigami T; Han F; Moriguchi S; Shibuya M; Iwabuchi Y; Fukunaga K
Neuroscience; 2007 Aug; 148(1):221-9. PubMed ID: 17629407
[TBL] [Abstract][Full Text] [Related]
14. Bis(6-ethylpicolinato)oxovanadium(IV) complex with normoglycemic activity in KK-A(y) mice.
Sasagawa T; Yoshikawa Y; Kawabe K; Sakurai H; Kojima Y
J Inorg Biochem; 2002 Jan; 88(1):108-12. PubMed ID: 11750032
[TBL] [Abstract][Full Text] [Related]
15. Severely impaired insulin signaling in chronic wounds of diabetic ob/ob mice: a potential role of tumor necrosis factor-alpha.
Goren I; Müller E; Pfeilschifter J; Frank S
Am J Pathol; 2006 Mar; 168(3):765-77. PubMed ID: 16507892
[TBL] [Abstract][Full Text] [Related]
16. Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes.
Araújo EP; De Souza CT; Ueno M; Cintra DE; Bertolo MB; Carvalheira JB; Saad MJ; Velloso LA
Endocrinology; 2007 Dec; 148(12):5991-7. PubMed ID: 17761768
[TBL] [Abstract][Full Text] [Related]
17. Bis(alpha-furancarboxylato)oxovanadium(IV) prevents and improves dexamethasone-induced insulin resistance in 3T3-L1 adipocytes.
Zuo YQ; Liu WP; Niu YF; Tian CF; Xie MJ; Chen XZ; Li L
J Pharm Pharmacol; 2008 Oct; 60(10):1335-40. PubMed ID: 18812026
[TBL] [Abstract][Full Text] [Related]
18. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice.
Emanuelli B; Peraldi P; Filloux C; Chavey C; Freidinger K; Hilton DJ; Hotamisligil GS; Van Obberghen E
J Biol Chem; 2001 Dec; 276(51):47944-9. PubMed ID: 11604392
[TBL] [Abstract][Full Text] [Related]
19. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
Fujiwara T; Yoshioka S; Yoshioka T; Ushiyama I; Horikoshi H
Diabetes; 1988 Nov; 37(11):1549-58. PubMed ID: 3053303
[TBL] [Abstract][Full Text] [Related]
20. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling.
Young PW; Cawthorne MA; Coyle PJ; Holder JC; Holman GD; Kozka IJ; Kirkham DM; Lister CA; Smith SA
Diabetes; 1995 Sep; 44(9):1087-92. PubMed ID: 7657033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
